tmao due to taking l carnitine. Frontiers γ-Butyrobetaine Is a Proatherogenic Intermediate
Description
The triglyceride-lowering effects of EPA and DHA increase with dose (106), but clinically meaningful reductions in serum triglyceride concentrations have been demonstrated at doses of 2 g/day of EPA + DHA (107)
Effects of long-term treatment with Acetyl-L-Carnitine
37,38 However, as we have discussed, the drug itself can cause toxicity without the presence of elevated drug levels
This plays a role in overall cardiovascular well-being
